The sleep apnea diagnostic systems market is valued at US$ 4.60 Billion in 2026 and is projected to reach US$ 5.77 Billion by 2033, growing at a CAGR of 3.3%.
Growth is driven by expanded sleep disorder screening in occupational health programs and increasing recognition of sleep apnea’s link with cardiovascular and metabolic diseases.
Polysomnography (PSG) devices hold the largest share at 45.0% due to their mandatory role in confirmed diagnosis for insurance reimbursement of CPAP therapy.
North America leads with 42.0% share in 2026, supported by strong reimbursement systems and a high number of accredited sleep laboratories.
The key opportunity lies in AI-based diagnostic tools and ambulatory sleep testing solutions that improve efficiency and address shortages of trained sleep technicians.